Skip to main content

A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old

Completed · Phase 2 · NCT02616302

Conditions: Gastroesophageal Reflux Disease (GERD)

At a glance

Research payments reported, 2025
$187,477
U.S. investigators named
6
Sites paid
6
Planned or actual enrollment
71

About the trial

Sponsor
Takeda
Tested
Dexlansoprazole (drug)
Dates
Started 2023-02-20; completion 2026-07-21
Results posted
Not yet

Gastroesophageal reflux disease (GERD) is caused by food or acid coming up from the stomach into the esophagus, repeatedly. The esophagus is the tube that carries food and liquids from the mouth to the stomach. The body uses stomach acid to break down food, but when acid rises up into the esophagus it can hurt or damage it. People with GERD often feel food coming back up into the throat and mouth and have a burning feeling in their stomach, chest, or throat, called heartburn. Other symptoms of GERD include pain in the stomach or throat, difficulty eating, and throwing up. Symptomatic nonerosive GERD is a condition where people have the symptoms of GERD but the esophagus has not been damag…

From ClinicalTrials.gov, last updated 2026-07-29. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Takeda Pharmaceuticals U.S.A., Inc. reported $187,477 in research payments for this study in 2025 (109 payments).

Products named: Dexilant

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.